Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600-mutant unresectable or metastatic melanoma (MM)

This article has no abstract
Epistemonikos ID: 028a0a5d948da912fca9e382564d44aa3049c8f9
First added on: Feb 08, 2025